

References

L-5041

1. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. *Am J Gastroenterol*. Oct 2002; 97(10): 2614-8. PMID 12385448
2. Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. *Hepatology*. Mar 2009; 49(3): 1017-44. PMID 19243014
3. Mehta SH, Lau B, Afdhal NH, et al. Exceeding the limits of liver histology markers. *J Hepatol*. Jan 2009; 50(1): 36-41. PMID 19012989
4. Trikalinos TA, Balion CM. Chapter 9: options for summarizing medical test performance in the absence of a "gold standard". *J Gen Intern Med*. Jun 2012; 27 Suppl 1: S67-75. PMID 22648677
5. Crossan C, Tsochatzis EA, Longworth L, et al. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. *Health Technol Assess*. Jan 2015; 19(9): 1-409, v-vi. PMID 25633908
6. Houot M, Ngo Y, Munteanu M, et al. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. *Aliment Pharmacol Ther*. Jan 2016; 43(1): 16-29. PMID 26516104
7. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. *Lancet*. Apr 07 2001; 357(9262): 1069-75. PMID 11297957
8. Poynard T, McHutchison J, Manns M, et al. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. *Hepatology*. Aug 2003; 38(2): 481-92. PMID 12883493
9. Poynard T, Munteanu M, Imbert-Bismut F, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. *Clin Chem*. Aug 2004; 50(8): 1344-55. PMID 15192028
10. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. *Am J Gastroenterol*. Jun 2004; 99(6): 1160-74. PMID 15180741
11. Lichtigagen R, Bahr MJ. Noninvasive diagnosis of fibrosis in chronic liver disease. *Expert Rev Mol Diagn*. Sep 2004; 4(5): 715-26. PMID 15347264
12. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. *N Engl J Med*. Apr 17 2014; 370(16): 1483-93. PMID 24725238

13. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. *N Engl J Med.* May 15 2014; 370(20): 1889-98. PMID 24725239
14. Curry MP, O'Leary JG, Bzowej N, et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. *N Engl J Med.* Dec 31 2015; 373(27): 2618-28. PMID 26569658
15. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. *N Engl J Med.* Dec 31 2015; 373(27): 2608-17. PMID 26575258
16. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. *N Engl J Med.* May 15 2014; 370(20): 1879-88. PMID 24720702
17. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. *N Engl J Med.* May 22 2014; 370(21): 1993-2001. PMID 24795201
18. Naveau S, Raynard B, Ratziu V, et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. *Clin Gastroenterol Hepatol.* Feb 2005; 3(2): 167-74. PMID 15704051
19. Ratziu V, Massard J, Charlotte F, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. *BMC Gastroenterol.* Feb 14 2006; 6: 6. PMID 16503961
20. Lassailly G, Caiazzo R, Hollebecque A, et al. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity. *Eur J Gastroenterol Hepatol.* Jun 2011; 23(6): 499-506. PMID 21499110
21. Poynard T, Ratziu V, Charlotte F, et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholic steato hepatitis in patients with non-alcoholic fatty liver disease. *BMC Gastroenterol.* Nov 10 2006; 6: 34. PMID 17096854
22. Mohamadnejad M, Montazeri G, Fazlollahi A, et al. Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virus related liver disease. *Am J Gastroenterol.* Nov 2006; 101(11): 2537-45. PMID 17029616
23. Zeng MD, Lu LG, Mao YM, et al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. *Hepatology.* Dec 2005; 42(6): 1437-45. PMID 16317674
24. Park MS, Kim BK, Cheong JY, et al. Discordance between liver biopsy and FibroTest in assessing liver fibrosis in chronic hepatitis B. *PLoS One.* 2013; 8(2): e55759. PMID 23405210

25. Salkic NN, Jovanovic P, Hauser G, et al. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis. *Am J Gastroenterol.* Jun 2014; 109(6): 796-809. PMID 24535095
26. Xu XY, Kong H, Song RX, et al. The effectiveness of noninvasive biomarkers to predict hepatitis B-related significant fibrosis and cirrhosis: a systematic review and meta-analysis of diagnostic test accuracy. *PLoS One.* 2014; 9(6): e100182. PMID 24964038
27. Wai CT, Cheng CL, Wee A, et al. Non-invasive models for predicting histology in patients with chronic hepatitis B. *Liver Int.* Aug 2006; 26(6): 666-72. PMID 16842322
28. Patel K, Gordon SC, Jacobson I, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. *J Hepatol.* Dec 2004; 41(6): 935-42. PMID 15582126
29. Mehta P, Ploutz-Snyder R, Nandi J, et al. Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C. *Am J Gastroenterol.* Apr 2008; 103(4): 928-36. PMID 18371145
30. Patel K, Nelson DR, Rockey DC, et al. Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C. *Clin Gastroenterol Hepatol.* Feb 2008; 6(2): 242-7. PMID 18187364
31. Snyder N, Nguyen A, Gajula L, et al. The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C. *Clin Chim Acta.* Jun 2007; 381(2): 119-23. PMID 17442291
32. Castellana M, Donghia R, Guerra V, et al. Fibrosis-4 Index vs Nonalcoholic Fatty Liver Disease Fibrosis Score in Identifying Advanced Fibrosis in Subjects With Nonalcoholic Fatty Liver Disease: A Meta-Analysis. *Am J Gastroenterol.* Sep 01 2021; 116(9): 1833-1841. PMID 34160377
33. Mozes FE, Lee JA, Selvaraj EA, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. *Gut.* May 2022; 71(5): 1006-1019. PMID 34001645
34. Sharma C, Cococcia S, Ellis N, et al. Systematic review: Accuracy of the enhanced liver fibrosis test for diagnosing advanced liver fibrosis and cirrhosis. *J Gastroenterol Hepatol.* Jul 2021; 36(7): 1788-1802. PMID 33668077
35. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology.* Aug 2003; 38(2): 518-26. PMID 12883497
36. Giannini EG, Zaman A, Ceppa P, et al. A simple approach to noninvasively identifying significant fibrosis in chronic hepatitis C patients in clinical practice. *J Clin Gastroenterol.* Jul 2006; 40(6): 521-7. PMID 16825935

37. Bourliere M, Penaranda G, Renou C, et al. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. *J Viral Hepat.* Oct 2006; 13(10): 659-70. PMID 16970597
38. Zarski JP, Sturm N, Guechot J, et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. *J Hepatol.* Jan 2012; 56(1): 55-62. PMID 21781944
39. Sebastiani G, Halfon P, Castera L, et al. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. *Hepatology.* Jun 2009; 49(6): 1821-7. PMID 19291784
40. Boursier J, de Ledinghen V, Zarski JP, et al. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. *Hepatology.* Jan 2012; 55(1): 58-67. PMID 21898504
41. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. *Gastroenterology.* Dec 2004; 127(6): 1704-13. PMID 15578508
42. Siemens Healthineers. Liver Fibrosis Assays: Enhanced Liver Fibrosis (ELF) Test. 2019. <https://www.siemens-healthineers.com/laboratory-diagnostics/assays-by-diseases-conditions/liver-disease/elf-test>. Accessed September 12, 2022.
43. Younossi ZM, Felix S, Jeffers T, et al. Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease. *JAMA Netw Open.* Sep 01 2021; 4(9): e2123923. PMID 34529067
44. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology.* Jun 2006; 43(6): 1317-25. PMID 16729309
45. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. *Hepatology.* Jul 2007; 46(1): 32-6. PMID 17567829
46. Yan LT, Wang LL, Yao J, et al. Total bile acid-to-cholesterol ratio as a novel noninvasive marker for significant liver fibrosis and cirrhosis in patients with non-cholestatic chronic hepatitis B virus infection. *Medicine (Baltimore).* Feb 2020; 99(8): e19248. PMID 32080129
47. Cianci N, Subhani M, Hill T, et al. Prognostic non-invasive biomarkers for all-cause mortality in non-alcoholic fatty liver disease: A systematic review and meta-analysis. *World J Hepatol.* May 27 2022; 14(5): 1025-1037. PMID 35721296
48. Sanyal AJ, Harrison SA, Ratziu V, et al. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. *Hepatology.* Dec 2019; 70(6): 1913-1927. PMID 30993748

49. National Institute for Health and Care Excellence (NICE). Non-alcoholic fatty liver disease (NAFLD): assessment and management [NG49]. 2016; <https://www.nice.org.uk/guidance/ng49>. Accessed September 13, 2022.
50. Brener S. Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis. *Ont Health Technol Assess Ser.* 2015; 15(18): 1-45. PMID 26664664
51. Bota S, Herkner H, Sporea I, et al. Meta-analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis. *Liver Int.* Sep 2013; 33(8): 1138-47. PMID 23859217
52. Chon YE, Choi EH, Song KJ, et al. Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. *PLoS One.* 2012; 7(9): e44930. PMID 23049764
53. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. *Gastroenterology.* Apr 2008; 134(4): 960-74. PMID 18395077
54. Kwok R, Tse YK, Wong GL, et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments. *Aliment Pharmacol Ther.* Feb 2014; 39(3): 254-69. PMID 24308774
55. Poynard T, Morra R, Ingiliz P, et al. Assessment of liver fibrosis: noninvasive means. *Saudi J Gastroenterol.* Oct 2008; 14(4): 163-73. PMID 19568532
56. Poynard T, Ngo Y, Munteanu M, et al. Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B. *Curr Hepat Rep.* Jun 2011; 10(2): 87-97. PMID 21654911
57. Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. *Am J Gastroenterol.* Nov 2007; 102(11): 2589-600. PMID 17850410
58. Shi KQ, Tang JZ, Zhu XL, et al. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy. *J Gastroenterol Hepatol.* Jun 2014; 29(6): 1149-58. PMID 24476011
59. Steadman R, Myers RP, Leggett L, et al. A health technology assessment of transient elastography in adult liver disease. *Can J Gastroenterol.* Mar 2013; 27(3): 149-58. PMID 23516679
60. Stebbing J, Farouk L, Panos G, et al. A meta-analysis of transient elastography for the detection of hepatic fibrosis. *J Clin Gastroenterol.* Mar 2010; 44(3): 214-9. PMID 19745758
61. Talwalkar JA, Kurtz DM, Schoenleber SJ, et al. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. *Clin Gastroenterol Hepatol.* Oct 2007; 5(10): 1214-20. PMID 17916549

62. Tsochatzis EA, Gurusamy KS, Ntaoula S, et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. *J Hepatol.* Apr 2011; 54(4): 650-9. PMID 21146892
63. Tsochatzis EA, Crossan C, Longworth L, et al. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. *Hepatology.* Sep 2014; 60(3): 832-43. PMID 25043847
64. Xu XY, Wang WS, Zhang QM, et al. Performance of common imaging techniques vs serum biomarkers in assessing fibrosis in patients with chronic hepatitis B: A systematic review and meta-analysis. *World J Clin Cases.* Aug 06 2019; 7(15): 2022-2037. PMID 31423434
65. Cai C, Song X, Chen X, et al. Transient Elastography in Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease: A Systemic Review and Meta-Analysis. *Can J Gastroenterol Hepatol.* 2021; 2021: 8859338. PMID 33542909
66. Geng XX, Huang RG, Lin JM, et al. Transient elastography in clinical detection of liver cirrhosis: A systematic review and meta-analysis. *Saudi J Gastroenterol.* Jul-Aug 2016; 22(4): 294-303. PMID 27488324
67. Jiang W, Huang S, Teng H, et al. Diagnostic accuracy of point shear wave elastography and transient elastography for staging hepatic fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis. *BMJ Open.* Aug 23 2018; 8(8): e021787. PMID 30139901
68. Li Y, Huang YS, Wang ZZ, et al. Systematic review with meta-analysis: the diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B. *Aliment Pharmacol Ther.* Feb 2016; 43(4): 458-69. PMID 26669632
69. Njei B, McCarty TR, Luk J, et al. Use of transient elastography in patients with HIV-HCV coinfection: A systematic review and meta-analysis. *J Gastroenterol Hepatol.* Oct 2016; 31(10): 1684-1693. PMID 26952020
70. Pavlov CS, Casazza G, Nikolova D, et al. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. *Cochrane Database Syst Rev.* Jan 22 2015; 1: CD010542. PMID 25612182
71. Xu X, Su Y, Song R, et al. Performance of transient elastography assessing fibrosis of single hepatitis B virus infection: a systematic review and meta-analysis of a diagnostic test. *Hepatol Int.* Oct 2015; 9(4): 558-66. PMID 26187292
72. Abdel Alem S, Elsharkawy A, El Akel W, et al. Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients. *Expert Rev Gastroenterol Hepatol.* Oct 2019; 13(10): 1009-1016. PMID 31418303
73. Beyer C, Hutton C, Andersson A, et al. Comparison between magnetic resonance and ultrasound-derived indicators of hepatic steatosis in a pooled NAFLD cohort. *PLoS One.* 2021; 16(4): e0249491. PMID 33793651

74. Imajo K, Tetlow L, Dennis A, et al. Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort. *World J Gastroenterol*. Feb 21 2021; 27(7): 609-623. PMID 33642832
75. McDonald N, Eddowes PJ, Hodson J, et al. Multiparametric magnetic resonance imaging for quantitation of liver disease: a two-centre cross-sectional observational study. *Sci Rep*. Jun 15 2018; 8(1): 9189. PMID 29907829
76. Jayaswal ANA, Levick C, Selvaraj EA, et al. Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood-based fibrosis markers in patients with chronic liver disease. *Liver Int*. Dec 2020; 40(12): 3071-3082. PMID 32730664
77. Pavlides M, Banerjee R, Sellwood J, et al. Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. *J Hepatol*. Feb 2016; 64(2): 308-315. PMID 26471505
78. Harrison SA, Dennis A, Fiore MM, et al. Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial. *PLoS One*. 2018; 13(9): e0203054. PMID 30192782
79. Nakajima A, Eguchi Y, Yoneda M, et al. Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor modulator (SPPARM), versus placebo in patients with non-alcoholic fatty liver disease. *Aliment Pharmacol Ther*. Nov 2021; 54(10): 1263-1277. PMID 34528723
80. Jayaswal ANA, Levick C, Collier J, et al. Liver cT 1 decreases following direct-acting antiviral therapy in patients with chronic hepatitis C virus. *Abdom Radiol (NY)*. May 2021; 46(5): 1947-1957. PMID 33247768
81. Janowski K, Shumbayawonda E, Dennis A, et al. Multiparametric MRI as a Noninvasive Monitoring Tool for Children With Autoimmune Hepatitis. *J Pediatr Gastroenterol Nutr*. Jan 01 2021; 72(1): 108-114. PMID 32925554
82. Arndtz K, Shumbayawonda E, Hodson J, et al. Multiparametric Magnetic Resonance Imaging, Autoimmune Hepatitis, and Prediction of Disease Activity. *Hepatol Commun*. Jun 2021; 5(6): 1009-1020. PMID 34141986
83. Bradley C, Scott RA, Cox E, et al. Short-term changes observed in multiparametric liver MRI following therapy with direct-acting antivirals in chronic hepatitis C virus patients. *Eur Radiol*. Jun 2019; 29(6): 3100-3107. PMID 30506214
84. Heneghan MA, Shumbayawonda E, Dennis A, et al. Quantitative magnetic resonance imaging to aid clinical decision making in autoimmune hepatitis. *EClinicalMedicine*. Apr 2022; 46: 101325. PMID 35340625
85. Guo Y, Parthasarathy S, Goyal P, et al. Magnetic resonance elastography and acoustic radiation force impulse for staging hepatic fibrosis: a meta-analysis. *Abdom Imaging*. Apr 2015; 40(4): 818-34. PMID 24711064

86. Hu X, Qiu L, Liu D, et al. Acoustic Radiation Force Impulse (ARFI) Elastography for non-invasive evaluation of hepatic fibrosis in chronic hepatitis B and C patients: a systematic review and meta-analysis. *Med Ultrason.* Jan 31 2017; 19(1): 23-31. PMID 28180193
87. Lin Y, Li H, Jin C, et al. The diagnostic accuracy of liver fibrosis in non-viral liver diseases using acoustic radiation force impulse elastography: A systematic review and meta-analysis. *PLoS One.* 2020; 15(1): e0227358. PMID 31940395
88. Liu H, Fu J, Hong R, et al. Acoustic Radiation Force Impulse Elastography for the Non-Invasive Evaluation of Hepatic Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review Meta-Analysis. *PLoS One.* 2015; 10(7): e0127782. PMID 26131717
89. Nierhoff J, Chavez Ortiz AA, Herrmann E, et al. The efficiency of acoustic radiation force impulse imaging for the staging of liver fibrosis: a meta-analysis. *Eur Radiol.* Nov 2013; 23(11): 3040-53. PMID 23801420
90. Singh S, Venkatesh SK, Wang Z, et al. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. *Clin Gastroenterol Hepatol.* Mar 2015; 13(3): 440-451.e6. PMID 25305349
91. Singh S, Venkatesh SK, Loomba R, et al. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis. *Eur Radiol.* May 2016; 26(5): 1431-40. PMID 26314479
92. Xiao G, Zhu S, Xiao X, et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. *Hepatology.* Nov 2017; 66(5): 1486-1501. PMID 28586172
93. Kobayashi K, Nakao H, Nishiyama T, et al. Diagnostic accuracy of real-time tissue elastography for the staging of liver fibrosis: a meta-analysis. *Eur Radiol.* Jan 2015; 25(1): 230-8. PMID 25149296
94. Hong H, Li J, Jin Y, et al. Performance of real-time elastography for the staging of hepatic fibrosis: a meta-analysis. *PLoS One.* 2014; 9(12): e115702. PMID 25541695
95. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. *Hepatology.* Jan 2018; 67(1): 328-357. PMID 28714183
96. Kanwal F, Shubrook JH, Adams LA, et al. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology.* Nov 2021; 161(5): 1657-1669. PMID 34602251
97. Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management

of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). *Endocr Pract.* May 2022; 28(5): 528-562. PMID 35569886

98. Singh S, Muir AJ, Dieterich DT, et al. American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases. *Gastroenterology.* May 2017; 152(6): 1544-1577. PMID 28442120
99. National Institute for Health and Care Excellence (NICE). Hepatitis B (chronic): diagnosis and management [CG165]. 2017; <https://www.nice.org.uk/guidance/cg165>. Accessed September 12, 2022.
100. American Association for the Study of Liver Diseases, Infectious Diseases Society of America. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Last updated March 12, 2022; <https://www.hcvguidelines.org>. Accessed September 12, 2022.
101. Bashir MR, Horowitz JM, Kamel IR, et al. ACR Appropriateness Criteria(R) Chronic Liver Disease. *J Am Coll Radiol.* May 2020; 17(5S): S70-S80. PMID 32370979
102. Owens DK, Davidson KW, Krist AH, et al. Screening for Hepatitis C Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. *JAMA.* Mar 10 2020; 323(10): 970-975. PMID 32119076